<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2843">
  <stage>Registered</stage>
  <submitdate>1/07/2010</submitdate>
  <approvaldate>1/07/2010</approvaldate>
  <nctid>NCT01164904</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20090107</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Amg 181

Experimental: Experimental - Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.


Treatment: drugs: Amg 181
Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)</outcome>
      <timepoint>Through study completion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize the pharmacokinetics (PK) of ascending single doses of AMG 181</outcome>
      <timepoint>Through study completion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize the pharmacodynamic (PD) effects of AMG 181 on receptor occupancy and on cell counts in selected lymphocyte subset populations</outcome>
      <timepoint>Through study completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Volunteers

          -  Healthy male or female subjects of non-reproductive potential between 18 to 45 year-of
             -age

          -  Body Mass Index (BMI) between 18 and 34 kg/m2

          -  Normal physical and neurological examination, clinical laboratory values and ECG

          -  Additional inclusion criteria apply

         Subjects with Mild to Moderate Ulcerative Colitis

          -  Male or female subjects between 18 to 55 year-of -age

          -  Body Mass Index (BMI) between 18 and 34 kg/m2

          -  Diagnosis of Ulcerative Colitis for at least 2 months

          -  Active, mild to moderate disease as defined by an Ulcerative Colitis Disease Activity
             Index (UCDAI, aka Mayo score) score of 4 to 9 (inclusive), with a minimum
             sigmoidoscopy score of 1

          -  Additional inclusion criteria apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria: Healthy Volunteers

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluations, procedures or completion

          -  History of malignancy of any type, other than in situ cervical cancer or surgically
             excised non-melanomatous skin cancers within the past 5 years

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  Additional exclusion criteria apply

        Exclusion criteria: Subjects with Mild to Moderate Ulcerative Colitis

          -  Disease limited to the rectum, i.e. within 20 cm of the anal verge

          -  Any prior gastrointestinal surgery

          -  Evidence of severe disease (as evidenced by an Hb concentration &lt;11g/dL; toxic
             megacolon, or an UCDAI score=10)

          -  Immunosuppressive therapy with either azathioprine, methotrexate, or mercaptopurine,
             within the past 3 months

          -  Prior exposure to a biologic agent or cyclosporine A

          -  Use of antibiotics within the past 2 weeks of screening and during screening period

          -  Use of topical (e.g. suppository or enema) mesalamine or steroids within two weeks
             prior to day 1

          -  Additional exclusion criteria apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>72</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Prahran</hospital>
    <hospital>Research Site - Nedlands</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Prahran</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses
      of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate
      ulcerative colitis (UC)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01164904</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>